BlackRock Inc. purchased a new position in shares of Exagen Inc. (NASDAQ:XGN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 142,625 shares of the company's stock, valued at approximately $663,000. BlackRock Inc. owned about 0.59% of Exagen at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Balyasny Asset Management L.P. grew its holdings in shares of Exagen by 27.1% during the 4th quarter. Balyasny Asset Management L.P. now owns 919,187 shares of the company's stock worth $5,589,000 after purchasing an additional 195,759 shares during the period. Vanguard Group Inc. increased its position in Exagen by 7.7% during the 3rd quarter. Vanguard Group Inc. now owns 733,824 shares of the company's stock worth $8,065,000 after purchasing an additional 52,205 shares in the last quarter. Invesco Ltd. purchased a new position in Exagen in the third quarter valued at approximately $7,420,000. Kennedy Capital Management LLC raised its holdings in Exagen by 77.6% in the third quarter. Kennedy Capital Management LLC now owns 551,848 shares of the company's stock valued at $6,065,000 after buying an additional 241,127 shares during the period. Finally, Wexford Capital LP lifted its position in Exagen by 6.9% during the third quarter. Wexford Capital LP now owns 444,927 shares of the company's stock valued at $4,890,000 after buying an additional 28,579 shares in the last quarter. 75.25% of the stock is currently owned by hedge funds and other institutional investors.
Exagen Price Performance
NASDAQ XGN opened at $7.58 on Monday. The stock has a market cap of $183.66 million, a PE ratio of -9.36 and a beta of 2.10. Exagen Inc. has a fifty-two week low of $2.59 and a fifty-two week high of $12.23. The business has a 50 day moving average price of $5.79 and a two-hundred day moving average price of $4.36. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 1.96.
Exagen (NASDAQ:XGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.06. The company had revenue of $19.94 million for the quarter, compared to analyst estimates of $17.80 million. Exagen had a negative net margin of 26.61% and a negative return on equity of 104.46%. As a group, sell-side analysts predict that Exagen Inc. will post -0.71 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
XGN has been the subject of several research reports. BTIG Research boosted their price objective on shares of Exagen from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. TD Cowen raised their target price on shares of Exagen from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Weiss Ratings restated a "sell (e+)" rating on shares of Exagen in a report on Friday, August 7th. Roth Capital began coverage on shares of Exagen in a research report on Wednesday, June 24th. They set a "buy" rating and a $8.00 price target for the company. Finally, B. Riley Financial reiterated a "buy" rating and issued a $12.00 price target (up from $8.00) on shares of Exagen in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Exagen has a consensus rating of "Moderate Buy" and a consensus price target of $9.62.
Check Out Our Latest Report on Exagen
About Exagen
(
Free Report)
Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.
The company's flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren's panel.
See Also
Want to see what other hedge funds are holding XGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exagen Inc. (NASDAQ:XGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
